Global AI-Enabled Drug Discovery and Clinical Trials Market: Analysis and Forecast, 2019-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Key Questions Answered in the Report:
The Global AI-Enabled Drug Discovery and Clinical Trials Market Report by BIS Research projects the market to grow at a significant CAGR of 24.88% during the forecast period from 2019 to 2030. The market has evolved dramatically with increasing drug development expenditure and growing synergistic activities.
Despite the benefits of these software solutions, the major challenges in the market are lack of regulations and ethical issues. Some of the major opportunities for the key vendors in the market could be investment opportunities in emerging economies such as India, China, and Brazil and the introduction of systems in different languages.
Expert Quote
“Biopharmaceutical companies are the major end users of the AI-enabled drug discovery and clinical trials market in terms of revenue share. The biopharmaceutical companies market share is expected to increase up to $2,692.8 million. However, the usage of the solutions is expected to increase in contract research organizations and academic & research centers in order to streamline the workflow of the facilities and improve the quality of care.”
Scope of the Market Intelligence on Global AI-Enabled Drug Discovery and Clinical Trials Market
The purpose of this study is to gain a holistic view of the global AI-enabled drug discovery and clinical trials market in terms of various influencing factors such as regional adoption trends, component types, applications, therapeutic applications, and end users.
The scope of this report constitutes an in-depth study of the global AI -enabled drug discovery and clinical trials market, including a thorough analysis of the products in the market as well as their adoption spanning different geographical regions. The market has been chiefly segmented into component type, application, therapeutic application, end user, and region. The report provides the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
Market Segmentation
The Global AI -Enabled Drug Discovery and Clinical Trials Market can be segmented on the basis of component type, application, therapeutic application, end user, and region. As of 2018, AI- enabled solutions accounted for $207.5 million and is expected to reach a value of $3,385.0 million by the end of 2030. In terms of growth, the end users and academic institutes and research centers segment is expected to grow at the highest CAGR of 25.45% during the forecast period.
As of 2018, North America is the largest shareholder for the overall market and is expected to reach a value of $2,460.5 million by the end of 2030, growing with a CAGR of 24.47% during the forecast period. However, a higher growth rate can be expected from the Asia-Pacific region, considering its improving healthcare infrastructure, overburdened healthcare system, and focus of ASEAN countries to be recognized as a medical tourism destination.
Although the adoption rate of the AI-enabled solutions has been moderate, the potential that lies in them is immense. The integration AI-enabled solutions in the healthcare facility will not only enhance medical research but also help research organizations in cost containment. To make the entire drug discovery and development process more efficient, the AI -enabled solutions can be integrated across various stakeholders, namely biopharmaceutical companies, contract research organizations (CROs), academic institutes, and research centers.
Key Companies in the Global AI-Enabled Drug Discovery and Clinical Trials Market
Some of the major key players in the global AI-enabled drug discovery and clinical trials market include Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc., Benevolent AI, Berg, LLC, Berkeley Lights, Inc., BioAge Labs, Inc., Biovista, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason, and Concerto HealthAI.
Key Questions Answered in the Report:
- How can AI integration in drug discovery and clinical trials decrease drug development expenditure?
- How are pharmaceutical/biopharmaceutical companies assisting in market development?
- How can regulatory bodies such as FDA accelerate the AI adoption within the drug discovery and development process?
- What is the present status of AI adoption in the drug discovery and development processes globally?
- Which companies are expected to emerge as the key players of the market?
- How are the companies operating in the market generating revenue?
- What are the key regulatory implications in developed and developing regions for AI-enabled drug discovery and clinical trials market?
- How can the companies expand in non-English speaking regions?
- Which therapeutic area (such as oncology and neurology) has the highest AI adoption rate in clinical trials?
- Which region is anticipated to serve as an emerging market for drug discovery and clinical trial, respectively?
- What is the state of AI adoption in the Middle East and Latin America?
- What are the different methodologies followed by the companies in the market for drug development?
The Global AI-Enabled Drug Discovery and Clinical Trials Market Report by BIS Research projects the market to grow at a significant CAGR of 24.88% during the forecast period from 2019 to 2030. The market has evolved dramatically with increasing drug development expenditure and growing synergistic activities.
Despite the benefits of these software solutions, the major challenges in the market are lack of regulations and ethical issues. Some of the major opportunities for the key vendors in the market could be investment opportunities in emerging economies such as India, China, and Brazil and the introduction of systems in different languages.
Expert Quote
“Biopharmaceutical companies are the major end users of the AI-enabled drug discovery and clinical trials market in terms of revenue share. The biopharmaceutical companies market share is expected to increase up to $2,692.8 million. However, the usage of the solutions is expected to increase in contract research organizations and academic & research centers in order to streamline the workflow of the facilities and improve the quality of care.”
Scope of the Market Intelligence on Global AI-Enabled Drug Discovery and Clinical Trials Market
The purpose of this study is to gain a holistic view of the global AI-enabled drug discovery and clinical trials market in terms of various influencing factors such as regional adoption trends, component types, applications, therapeutic applications, and end users.
The scope of this report constitutes an in-depth study of the global AI -enabled drug discovery and clinical trials market, including a thorough analysis of the products in the market as well as their adoption spanning different geographical regions. The market has been chiefly segmented into component type, application, therapeutic application, end user, and region. The report provides the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.
Market Segmentation
The Global AI -Enabled Drug Discovery and Clinical Trials Market can be segmented on the basis of component type, application, therapeutic application, end user, and region. As of 2018, AI- enabled solutions accounted for $207.5 million and is expected to reach a value of $3,385.0 million by the end of 2030. In terms of growth, the end users and academic institutes and research centers segment is expected to grow at the highest CAGR of 25.45% during the forecast period.
As of 2018, North America is the largest shareholder for the overall market and is expected to reach a value of $2,460.5 million by the end of 2030, growing with a CAGR of 24.47% during the forecast period. However, a higher growth rate can be expected from the Asia-Pacific region, considering its improving healthcare infrastructure, overburdened healthcare system, and focus of ASEAN countries to be recognized as a medical tourism destination.
Although the adoption rate of the AI-enabled solutions has been moderate, the potential that lies in them is immense. The integration AI-enabled solutions in the healthcare facility will not only enhance medical research but also help research organizations in cost containment. To make the entire drug discovery and development process more efficient, the AI -enabled solutions can be integrated across various stakeholders, namely biopharmaceutical companies, contract research organizations (CROs), academic institutes, and research centers.
Key Companies in the Global AI-Enabled Drug Discovery and Clinical Trials Market
Some of the major key players in the global AI-enabled drug discovery and clinical trials market include Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc., Benevolent AI, Berg, LLC, Berkeley Lights, Inc., BioAge Labs, Inc., Biovista, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason, and Concerto HealthAI.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 SCOPE OF THE REPORT
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Companies Profiled
3.5 Assumptions and Limitations
4 INDUSTRY ANALYSIS
4.1 Industry Trends
4.1.1 Incorporation Trends
4.2 Value Analysis
4.2.1 Drug Discovery
4.2.2 Clinical Trials
4.3 Regulatory Framework and Government Initiatives
4.3.1 Regulatory Framework in North America
4.3.2 Regulatory Framework in Europe
4.3.3 Government Initiatives
4.3.3.1 Government Initiatives in North America
4.3.3.2 Government Initiatives in Europe
5 PIPELINE ANALYSIS
6 COMPETITIVE LANDSCAPE
6.1 Key Developments and Strategies
6.1.1 Collaborations and Partnerships
6.1.2 Funding
6.1.3 Product Launch and Upgradation
6.1.4 Mergers and Acquisitions
6.1.5 Others
6.2 Business Model Analysis
6.2.1 Subscription
6.2.2 Software as a Service and Platform as a Service (SaaS and PaaS)
6.2.3 Pay Per Use Model
6.3 Competitive Benchmarking
7 MARKET DYNAMICS
7.1 Market Drivers
7.1.1 Increasing Drug Development Expenditure
7.1.2 Facilitation of Polypharmacology
7.1.3 Growing Number of Synergistic Activities
7.2 Market Restraints
7.2.1 Lack of Regulations
7.2.2 Ethical Issues
7.3 Market Opportunities
7.3.1 Expansion of Business in Developing Economies such as India and Brazil
7.3.2 Introduction of Solutions in Different Languages
8 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET
8.1 Assumptions and Limitations
8.2 Key Findings and Opportunity Assessment
8.2.1 Key Findings
8.2.2 Opportunity Assessment
9 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY COMPONENT)
9.1 Overview
9.2 Solutions
9.3 Services
10 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY APPLICATION)
10.1 Overview
10.2 Data Aggregation and Analysis
10.3 Clinical Trials
10.4 Drug Design
10.5 Drug Characterization
10.6 Biomarker Research
11 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY THERAPEUTIC APPLICATIONS)
11.1 Overview
11.2 Oncology
11.3 Cardiovascular Diseases
11.4 Nervous System Diseases
11.5 Respiratory Disorder
11.6 Metabolic Diseases
11.7 Immunologic Diseases
11.8 Infectious Diseases
11.9 Others
12 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY END USER)
12.1 Overview
12.2 Biopharmaceutical Industry
12.3 Contract Research Organizations (CROs)
12.4 Academic Institutes and Research Centers
13 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY REGION)
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 South Korea
13.4.4 Australia
13.4.5 India
13.4.6 Rest-of-Asia-Pacific
13.5 Rest-of-the-World
14 COMPANY PROFILES
14.1 Accutar Biotechnology Inc.
14.1.1 Company Overview
14.1.2 Role of Accutar Biotechnology Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.1.3 SWOT Analysis
14.2 AiCure, LLC
14.2.1 Company Overview
14.2.2 Role of AiCure, LLC in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.2.3 SWOT Analysis
14.3 Ardigen
14.3.1 Company Overview
14.3.2 Role of Ardigen in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.3.3 SWOT Analysis
14.4 Atomwise, Inc.
14.4.1 Company Overview
14.4.2 Role of Atomwise, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.4.3 SWOT Analysis
14.5 BenevolentAI
14.5.1 Company Overview
14.5.2 Role of BenevolentAI in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.5.3 SWOT Analysis
14.6 Berg LLC
14.6.1 Company Overview
14.6.2 Role of Berg LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.6.3 SWOT Analysis
14.7 Berkeley Lights, Inc.
14.7.1 Company Overview
14.7.2 Role of Berkeley Lights, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.7.3 SWOT Analysis
14.8 BioAge Labs, Inc.
14.8.1 Company Overview
14.8.2 Role of BioAge Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.8.3 SWOT Analysis
14.9 Biovista Inc.
14.9.1 Company Overview
14.9.2 Role of Biovista Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.9.3 SWOT Analysis
14.10 C4X Discovery Holdings Plc
14.10.1 Company Overview
14.10.2 Role of C4X Discovery Holdings Plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.10.3 Financials
14.10.4 Key Insights About the Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Clinithink Ltd
14.11.1 Company Overview
14.11.2 Role of Clinithink Ltd in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.11.3 SWOT Analysis
14.12 Cloud Pharmaceuticals, Inc.
14.12.1 Company Overview
14.12.2 Role of Cloud Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.12.3 SWOT Analysis
14.13 Cyclica, Inc.
14.13.1 Company Overview
14.13.2 Role of Cyclica, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.13.3 SWOT Analysis
14.14 CytoReason
14.14.1 Company Overview
14.14.2 Role of CytoReason in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.14.3 SWOT Analysis
14.15 Symphony Innovation, LLC
14.15.1 Company Overview
14.15.2 Role of Symphony Innovation, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.15.3 SWOT Analysis
Company Snapshots
14.16 Deep Genomics Inc.
14.16.1 Company Overview
14.16.2 Role of Deep Genomics Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.17 DeepThink Health Inc.
14.17.1 Company Overview
14.17.2 Role of DeepThink Health Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.18 Envisagenics, Inc.
14.18.1 Company Overview
14.18.2 Role of Envisagenics, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.19 Exscientia Limited
14.19.1 Company Overview
14.19.2 Role of Exscientia Limited in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.20 e-therapeutics plc
14.20.1 Company Overview
14.20.2 Role of e-therapeutics plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.20.3 Financials
14.21 GNS Healthcare
14.21.1 Company Overview
14.21.2 Role of GNS Healthcare in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.22 Insilico Medicine
14.22.1 Company Overview
14.22.2 Role of Insilico Medicine in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.23 Lantern Pharma Inc.
14.23.1 Company Overview
14.23.2 Role of Lantern Pharma Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.24 Medable, Inc.
14.24.1 Company Overview
14.24.2 Role of Medable, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.25 Mind the Byte
14.25.1 Company Overview
14.25.2 Role of Mind the Byte in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.26 NuMedii, Inc
14.26.1 Company Overview
14.26.2 Role of NuMedii, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.27 Nuritas, Ltd.
14.27.1 Company Overview
14.27.2 Role of Nuritas, Ltd. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.28 Owkin, Inc.
14.28.1 Company Overview
14.28.2 Role of Owkin, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.29 Recursion Pharmaceuticals, Inc.
14.29.1 Company Overview
14.29.2 Role of Recursion Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.30 Schrцdinger, LLC
14.30.1 Company Overview
14.30.2 Role of Schrцdinger, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.31 TARA Biosystems, Inc.
14.31.1 Company Overview
14.31.2 Role of TARA Biosystems, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.32 twoXAR, Incorporated
14.32.1 Company Overview
14.32.2 Role of twoXAR, Incorporated in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.33 Verge Analytics, Inc.
14.33.1 Company Overview
14.33.2 Role of Verge Analytics, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.34 Winterlight Labs Inc.
14.34.1 Company Overview
14.34.2 Role of Winterlight Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.35 WuXi Nextcode Genomics
14.35.1 Company Overview
14.35.2 Role of WuXi Nextcode Genomics in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.36 XtalPi Inc.
14.36.1 Company Overview
14.36.2 Role of XtalPi Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 SCOPE OF THE REPORT
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Companies Profiled
3.5 Assumptions and Limitations
4 INDUSTRY ANALYSIS
4.1 Industry Trends
4.1.1 Incorporation Trends
4.2 Value Analysis
4.2.1 Drug Discovery
4.2.2 Clinical Trials
4.3 Regulatory Framework and Government Initiatives
4.3.1 Regulatory Framework in North America
4.3.2 Regulatory Framework in Europe
4.3.3 Government Initiatives
4.3.3.1 Government Initiatives in North America
4.3.3.2 Government Initiatives in Europe
5 PIPELINE ANALYSIS
6 COMPETITIVE LANDSCAPE
6.1 Key Developments and Strategies
6.1.1 Collaborations and Partnerships
6.1.2 Funding
6.1.3 Product Launch and Upgradation
6.1.4 Mergers and Acquisitions
6.1.5 Others
6.2 Business Model Analysis
6.2.1 Subscription
6.2.2 Software as a Service and Platform as a Service (SaaS and PaaS)
6.2.3 Pay Per Use Model
6.3 Competitive Benchmarking
7 MARKET DYNAMICS
7.1 Market Drivers
7.1.1 Increasing Drug Development Expenditure
7.1.2 Facilitation of Polypharmacology
7.1.3 Growing Number of Synergistic Activities
7.2 Market Restraints
7.2.1 Lack of Regulations
7.2.2 Ethical Issues
7.3 Market Opportunities
7.3.1 Expansion of Business in Developing Economies such as India and Brazil
7.3.2 Introduction of Solutions in Different Languages
8 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET
8.1 Assumptions and Limitations
8.2 Key Findings and Opportunity Assessment
8.2.1 Key Findings
8.2.2 Opportunity Assessment
9 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY COMPONENT)
9.1 Overview
9.2 Solutions
9.3 Services
10 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY APPLICATION)
10.1 Overview
10.2 Data Aggregation and Analysis
10.3 Clinical Trials
10.4 Drug Design
10.5 Drug Characterization
10.6 Biomarker Research
11 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY THERAPEUTIC APPLICATIONS)
11.1 Overview
11.2 Oncology
11.3 Cardiovascular Diseases
11.4 Nervous System Diseases
11.5 Respiratory Disorder
11.6 Metabolic Diseases
11.7 Immunologic Diseases
11.8 Infectious Diseases
11.9 Others
12 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY END USER)
12.1 Overview
12.2 Biopharmaceutical Industry
12.3 Contract Research Organizations (CROs)
12.4 Academic Institutes and Research Centers
13 GLOBAL AI-ENABLED DRUG DISCOVERY AND CLINICAL TRIALS MARKET (BY REGION)
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 South Korea
13.4.4 Australia
13.4.5 India
13.4.6 Rest-of-Asia-Pacific
13.5 Rest-of-the-World
14 COMPANY PROFILES
14.1 Accutar Biotechnology Inc.
14.1.1 Company Overview
14.1.2 Role of Accutar Biotechnology Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.1.3 SWOT Analysis
14.2 AiCure, LLC
14.2.1 Company Overview
14.2.2 Role of AiCure, LLC in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.2.3 SWOT Analysis
14.3 Ardigen
14.3.1 Company Overview
14.3.2 Role of Ardigen in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.3.3 SWOT Analysis
14.4 Atomwise, Inc.
14.4.1 Company Overview
14.4.2 Role of Atomwise, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.4.3 SWOT Analysis
14.5 BenevolentAI
14.5.1 Company Overview
14.5.2 Role of BenevolentAI in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.5.3 SWOT Analysis
14.6 Berg LLC
14.6.1 Company Overview
14.6.2 Role of Berg LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.6.3 SWOT Analysis
14.7 Berkeley Lights, Inc.
14.7.1 Company Overview
14.7.2 Role of Berkeley Lights, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.7.3 SWOT Analysis
14.8 BioAge Labs, Inc.
14.8.1 Company Overview
14.8.2 Role of BioAge Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.8.3 SWOT Analysis
14.9 Biovista Inc.
14.9.1 Company Overview
14.9.2 Role of Biovista Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.9.3 SWOT Analysis
14.10 C4X Discovery Holdings Plc
14.10.1 Company Overview
14.10.2 Role of C4X Discovery Holdings Plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.10.3 Financials
14.10.4 Key Insights About the Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Clinithink Ltd
14.11.1 Company Overview
14.11.2 Role of Clinithink Ltd in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.11.3 SWOT Analysis
14.12 Cloud Pharmaceuticals, Inc.
14.12.1 Company Overview
14.12.2 Role of Cloud Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.12.3 SWOT Analysis
14.13 Cyclica, Inc.
14.13.1 Company Overview
14.13.2 Role of Cyclica, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.13.3 SWOT Analysis
14.14 CytoReason
14.14.1 Company Overview
14.14.2 Role of CytoReason in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.14.3 SWOT Analysis
14.15 Symphony Innovation, LLC
14.15.1 Company Overview
14.15.2 Role of Symphony Innovation, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.15.3 SWOT Analysis
Company Snapshots
14.16 Deep Genomics Inc.
14.16.1 Company Overview
14.16.2 Role of Deep Genomics Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.17 DeepThink Health Inc.
14.17.1 Company Overview
14.17.2 Role of DeepThink Health Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.18 Envisagenics, Inc.
14.18.1 Company Overview
14.18.2 Role of Envisagenics, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.19 Exscientia Limited
14.19.1 Company Overview
14.19.2 Role of Exscientia Limited in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.20 e-therapeutics plc
14.20.1 Company Overview
14.20.2 Role of e-therapeutics plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.20.3 Financials
14.21 GNS Healthcare
14.21.1 Company Overview
14.21.2 Role of GNS Healthcare in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.22 Insilico Medicine
14.22.1 Company Overview
14.22.2 Role of Insilico Medicine in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.23 Lantern Pharma Inc.
14.23.1 Company Overview
14.23.2 Role of Lantern Pharma Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.24 Medable, Inc.
14.24.1 Company Overview
14.24.2 Role of Medable, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.25 Mind the Byte
14.25.1 Company Overview
14.25.2 Role of Mind the Byte in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.26 NuMedii, Inc
14.26.1 Company Overview
14.26.2 Role of NuMedii, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.27 Nuritas, Ltd.
14.27.1 Company Overview
14.27.2 Role of Nuritas, Ltd. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.28 Owkin, Inc.
14.28.1 Company Overview
14.28.2 Role of Owkin, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.29 Recursion Pharmaceuticals, Inc.
14.29.1 Company Overview
14.29.2 Role of Recursion Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.30 Schrцdinger, LLC
14.30.1 Company Overview
14.30.2 Role of Schrцdinger, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.31 TARA Biosystems, Inc.
14.31.1 Company Overview
14.31.2 Role of TARA Biosystems, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.32 twoXAR, Incorporated
14.32.1 Company Overview
14.32.2 Role of twoXAR, Incorporated in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.33 Verge Analytics, Inc.
14.33.1 Company Overview
14.33.2 Role of Verge Analytics, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.34 Winterlight Labs Inc.
14.34.1 Company Overview
14.34.2 Role of Winterlight Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
14.35 WuXi Nextcode Genomics
14.35.1 Company Overview
14.35.2 Role of WuXi Nextcode Genomics in Global AI-Enabled Drug Discovery and Clinical Trials Market
14.36 XtalPi Inc.
14.36.1 Company Overview
14.36.2 Role of XtalPi Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
LIST OF TABLES
Table 4.1: AI Incorporation by Healthcare Companies
Table 4.2: Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in North America
Table 4.3: Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
Table 4.4: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in North America
Table 4.5: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
Table 5.1: AI-Enabled Drugs Pipeline
Table 6.1: Competitive Benchmarking: Global AI-Enabled Drug Discovery and Clinical Trials Market
Table 10.1: Solution Providers: Drug Characterization
Table 13.1: Rest-of-the-World: Country-Wise Analysis, 2019-2030
Table 4.1: AI Incorporation by Healthcare Companies
Table 4.2: Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in North America
Table 4.3: Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
Table 4.4: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in North America
Table 4.5: Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
Table 5.1: AI-Enabled Drugs Pipeline
Table 6.1: Competitive Benchmarking: Global AI-Enabled Drug Discovery and Clinical Trials Market
Table 10.1: Solution Providers: Drug Characterization
Table 13.1: Rest-of-the-World: Country-Wise Analysis, 2019-2030
LIST OF FIGURES
Figure 1: Global AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 2: Impact Analysis
Figure 3: Share of Different Strategies
Figure 4: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Component 2018 vs. 2030 ($Million)
Figure 5: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Application, 2018 vs. 2030 ($Million)
Figure 6: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Therapeutic Application, 2018 vs. 2030 ($Million)
Figure 7: Global AI-Enabled Drug Discovery and Clinical Trials Market, by End User, 2018 vs. 2030 ($Million)
Figure 8: Global AI-Enabled Drug Discovery and Clinical Trials Market Snapshot
Figure 2.1: Global AI-Enabled Drug Discovery and Clinical Trials Market Segmentation
Figure 3.1: Global AI-Enabled Drug Discovery and Clinical Trials Market Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Value Analysis: Drug Discovery
Figure 4.2: Stages of Clinical Trials
Figure 6.1: Share of Key Developments and Strategies, 2016-2019
Figure 6.2: Collaborations and Partnerships Share (by Company), 2016-2019
Figure 6.3: Funding Activity Share (by Company), 2016-2019
Figure 6.4: Product Launches (by Company), 2016-2019
Figure 6.5: Mergers and Acquisitions (by Company), 2016-2019
Figure 6.6: Other Activities (by Share), 2016-2019
Figure 7.1: Rising Drug Development Expenditure ($Billion), 1970s-2010s
Figure 7.2: Pharmaceutical vs. Government R&D Expenditure, 2014
Figure 9.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Component)
Figure 9.2: AI-Enabled Solutions for Drug Discovery and Clinical Trials: Usage Areas
Figure 9.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Solutions), 2018-2030
Figure 9.4: Global AI-Enabled Drug Discovery and Clinical Trials Market (Services), 2018-2030
Figure 10.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)
Figure 10.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (Data Aggregation and Analysis), 2018-2030
Figure 10.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Clinical Trials), 2018-2030
Figure 10.4: Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Design), 2018-2030
Figure 10.5: Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Characterization), 2018-2030
Figure 10.6: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biomarker Research), 2018-2030
Figure 11.1: AI Usage: Therapeutic Sections
Figure 11.2: AI-Enabled Oncology Clinical Trials (by Country)
Figure 11.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Oncology), 2018-2030
Figure 11.4: AI-Enabled Cardiovascular Diseases Clinical Trials (by Country)
Figure 11.5: Global AI-Enabled Drug Discovery and Clinical Trials Market (Cardiovascular Diseases), 2018-2030
Figure 11.6: AI-Enabled Nervous System Diseases Clinical Trials (by Country)
Figure 11.7: Global AI-Enabled Drug Discovery and Clinical Trials Market (Nervous System Diseases), 2018-2030
Figure 11.8: AI-Enabled Respiratory Disorders Clinical Trials (by Country)
Figure 11.9: Global AI-Enabled Drug Discovery and Clinical Trials Market (Respiratory Disorder), 2018-2030
Figure 11.10: AI-Enabled Metabolic Diseases Clinical Trials (by Country)
Figure 11.11: Global AI-Enabled Drug Discovery and Clinical Trials Market (Metabolic Diseases), 2018-2030
Figure 11.12: AI-Enabled Immunologic Diseases Clinical Trials (by Country)
Figure 11.13: Global AI-Enabled Drug Discovery and Clinical Trials Market (Immunologic Diseases), 2018-2030
Figure 11.14: Global AI-Enabled Drug Discovery and Clinical Trials Market (Infectious Diseases), 2018-2030
Figure 11.15: Global AI-Enabled Drug Discovery and Clinical Trials Market (Others), 2018-2030
Figure 12.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biopharmaceutical Industry), 2018-2030
Figure 12.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (CROs), 2018-2030
Figure 12.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Academic Institutes and Research Centers), 2018-2030
Figure 13.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region)
Figure 13.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region) 2018 vs. 2030
Figure 13.3: North America AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: North America AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs. 2030
Figure 13.6: U.S. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.7: Canada AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.8: Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018-2030
Figure 13.11: Germany AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.12: U.K. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.13: France AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.14: Italy AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.15: Spain AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.16: Rest-of-Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.17: Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.18: Asia-Pacific: Market Dynamics
Figure 13.19: Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs 2030
Figure 13.20: China AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.21: Japan AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.22: South Korea AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.23: Australia AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.24: India AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.25: Rest-of-Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.26: Rest-of-the-World AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 14.1: Accutar Biotechnology Inc.: Product Offerings
Figure 14.2: Accutar Biotechnology Inc.: SWOT Analysis
Figure 14.3: AiCure, LLC: Product Offerings
Figure 14.4: AiCure, LLC: SWOT Analysis
Figure 14.5: Ardigen: Product Offerings
Figure 14.6: Ardigen: SWOT Analysis
Figure 14.7: Atomwise, Inc.: Product Offerings
Figure 14.8: Atomwise, Inc.: SWOT Analysis
Figure 14.9: BenevolentAI: Product Offerings
Figure 14.10: BenevolentAI.: SWOT Analysis
Figure 14.11: Berg LLC: Product Offerings
Figure 14.12: Berg LLC: SWOT Analysis
Figure 14.13: Berkeley Lights, Inc.: Product Offerings
Figure 14.14: Berkeley Lights, Inc.: SWOT Analysis
Figure 14.15: BioAge Labs, Inc.: Product Offerings
Figure 14.16: BioAge Labs, Inc.: SWOT Analysis
Figure 14.17: Biovista Inc.: Product Offerings
Figure 14.18: Biovista Inc.: SWOT Analysis
Figure 14.19: C4X Discovery Holdings Plc: Product Offerings
Figure 14.20: C4X Discovery Holdings Plc: Overall Financials (2016-2018)
Figure 14.21: C4X Discovery Holdings Plc: R&D Expenditure (2016-2018)
Figure 14.22: C4X Discovery Holdings Plc.: SWOT Analysis
Figure 14.23: Clinithink Ltd: Product Offerings
Figure 14.24: Clinithink Ltd: SWOT Analysis
Figure 14.25: Cloud Pharmaceuticals: Product Offerings
Figure 14.26: Cloud Pharmaceuticals, Inc.: SWOT Analysis
Figure 14.27: Cyclica, Inc.: Product Offerings
Figure 14.28: Cyclica, Inc.: SWOT Analysis
Figure 14.29: CytoReason.: Product Offerings
Figure 14.30: CytoReason: SWOT Analysis
Figure 14.31: Concerto HealthAI: Product Offerings
Figure 14.32: Concerto HealthAI: SWOT Analysis
Figure 14.33: e-therapeutics plc: Overall Financials (2016-2018)
Figure 14.34: e-therapeutics plc: R&D Expenditure (2016-2018)
Figure 1: Global AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 2: Impact Analysis
Figure 3: Share of Different Strategies
Figure 4: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Component 2018 vs. 2030 ($Million)
Figure 5: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Application, 2018 vs. 2030 ($Million)
Figure 6: Global AI-Enabled Drug Discovery and Clinical Trials Market, by Therapeutic Application, 2018 vs. 2030 ($Million)
Figure 7: Global AI-Enabled Drug Discovery and Clinical Trials Market, by End User, 2018 vs. 2030 ($Million)
Figure 8: Global AI-Enabled Drug Discovery and Clinical Trials Market Snapshot
Figure 2.1: Global AI-Enabled Drug Discovery and Clinical Trials Market Segmentation
Figure 3.1: Global AI-Enabled Drug Discovery and Clinical Trials Market Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Value Analysis: Drug Discovery
Figure 4.2: Stages of Clinical Trials
Figure 6.1: Share of Key Developments and Strategies, 2016-2019
Figure 6.2: Collaborations and Partnerships Share (by Company), 2016-2019
Figure 6.3: Funding Activity Share (by Company), 2016-2019
Figure 6.4: Product Launches (by Company), 2016-2019
Figure 6.5: Mergers and Acquisitions (by Company), 2016-2019
Figure 6.6: Other Activities (by Share), 2016-2019
Figure 7.1: Rising Drug Development Expenditure ($Billion), 1970s-2010s
Figure 7.2: Pharmaceutical vs. Government R&D Expenditure, 2014
Figure 9.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Component)
Figure 9.2: AI-Enabled Solutions for Drug Discovery and Clinical Trials: Usage Areas
Figure 9.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Solutions), 2018-2030
Figure 9.4: Global AI-Enabled Drug Discovery and Clinical Trials Market (Services), 2018-2030
Figure 10.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)
Figure 10.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (Data Aggregation and Analysis), 2018-2030
Figure 10.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Clinical Trials), 2018-2030
Figure 10.4: Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Design), 2018-2030
Figure 10.5: Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Characterization), 2018-2030
Figure 10.6: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biomarker Research), 2018-2030
Figure 11.1: AI Usage: Therapeutic Sections
Figure 11.2: AI-Enabled Oncology Clinical Trials (by Country)
Figure 11.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Oncology), 2018-2030
Figure 11.4: AI-Enabled Cardiovascular Diseases Clinical Trials (by Country)
Figure 11.5: Global AI-Enabled Drug Discovery and Clinical Trials Market (Cardiovascular Diseases), 2018-2030
Figure 11.6: AI-Enabled Nervous System Diseases Clinical Trials (by Country)
Figure 11.7: Global AI-Enabled Drug Discovery and Clinical Trials Market (Nervous System Diseases), 2018-2030
Figure 11.8: AI-Enabled Respiratory Disorders Clinical Trials (by Country)
Figure 11.9: Global AI-Enabled Drug Discovery and Clinical Trials Market (Respiratory Disorder), 2018-2030
Figure 11.10: AI-Enabled Metabolic Diseases Clinical Trials (by Country)
Figure 11.11: Global AI-Enabled Drug Discovery and Clinical Trials Market (Metabolic Diseases), 2018-2030
Figure 11.12: AI-Enabled Immunologic Diseases Clinical Trials (by Country)
Figure 11.13: Global AI-Enabled Drug Discovery and Clinical Trials Market (Immunologic Diseases), 2018-2030
Figure 11.14: Global AI-Enabled Drug Discovery and Clinical Trials Market (Infectious Diseases), 2018-2030
Figure 11.15: Global AI-Enabled Drug Discovery and Clinical Trials Market (Others), 2018-2030
Figure 12.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (Biopharmaceutical Industry), 2018-2030
Figure 12.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (CROs), 2018-2030
Figure 12.3: Global AI-Enabled Drug Discovery and Clinical Trials Market (Academic Institutes and Research Centers), 2018-2030
Figure 13.1: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region)
Figure 13.2: Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region) 2018 vs. 2030
Figure 13.3: North America AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.4: North America: Market Dynamics
Figure 13.5: North America AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs. 2030
Figure 13.6: U.S. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.7: Canada AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.8: Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018-2030
Figure 13.11: Germany AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.12: U.K. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.13: France AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.14: Italy AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.15: Spain AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.16: Rest-of-Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.17: Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.18: Asia-Pacific: Market Dynamics
Figure 13.19: Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs 2030
Figure 13.20: China AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.21: Japan AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.22: South Korea AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.23: Australia AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.24: India AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.25: Rest-of-Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.26: Rest-of-the-World AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 14.1: Accutar Biotechnology Inc.: Product Offerings
Figure 14.2: Accutar Biotechnology Inc.: SWOT Analysis
Figure 14.3: AiCure, LLC: Product Offerings
Figure 14.4: AiCure, LLC: SWOT Analysis
Figure 14.5: Ardigen: Product Offerings
Figure 14.6: Ardigen: SWOT Analysis
Figure 14.7: Atomwise, Inc.: Product Offerings
Figure 14.8: Atomwise, Inc.: SWOT Analysis
Figure 14.9: BenevolentAI: Product Offerings
Figure 14.10: BenevolentAI.: SWOT Analysis
Figure 14.11: Berg LLC: Product Offerings
Figure 14.12: Berg LLC: SWOT Analysis
Figure 14.13: Berkeley Lights, Inc.: Product Offerings
Figure 14.14: Berkeley Lights, Inc.: SWOT Analysis
Figure 14.15: BioAge Labs, Inc.: Product Offerings
Figure 14.16: BioAge Labs, Inc.: SWOT Analysis
Figure 14.17: Biovista Inc.: Product Offerings
Figure 14.18: Biovista Inc.: SWOT Analysis
Figure 14.19: C4X Discovery Holdings Plc: Product Offerings
Figure 14.20: C4X Discovery Holdings Plc: Overall Financials (2016-2018)
Figure 14.21: C4X Discovery Holdings Plc: R&D Expenditure (2016-2018)
Figure 14.22: C4X Discovery Holdings Plc.: SWOT Analysis
Figure 14.23: Clinithink Ltd: Product Offerings
Figure 14.24: Clinithink Ltd: SWOT Analysis
Figure 14.25: Cloud Pharmaceuticals: Product Offerings
Figure 14.26: Cloud Pharmaceuticals, Inc.: SWOT Analysis
Figure 14.27: Cyclica, Inc.: Product Offerings
Figure 14.28: Cyclica, Inc.: SWOT Analysis
Figure 14.29: CytoReason.: Product Offerings
Figure 14.30: CytoReason: SWOT Analysis
Figure 14.31: Concerto HealthAI: Product Offerings
Figure 14.32: Concerto HealthAI: SWOT Analysis
Figure 14.33: e-therapeutics plc: Overall Financials (2016-2018)
Figure 14.34: e-therapeutics plc: R&D Expenditure (2016-2018)
